RXRX vs. FUSN, TWST, SDGR, DNA, BEAM, SANA, INBX, KYMR, APGE, and ADMA
Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Fusion Pharmaceuticals (FUSN), Twist Bioscience (TWST), Schrödinger (SDGR), Ginkgo Bioworks (DNA), Beam Therapeutics (BEAM), Sana Biotechnology (SANA), Inhibrx (INBX), Kymera Therapeutics (KYMR), Apogee Therapeutics (APGE), and ADMA Biologics (ADMA). These companies are all part of the "medical" sector.
Fusion Pharmaceuticals (NASDAQ:FUSN) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, dividends, media sentiment, risk and earnings.
72.9% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 7.8% of Fusion Pharmaceuticals shares are owned by company insiders. Comparatively, 15.8% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Recursion Pharmaceuticals has a net margin of -735.99% compared to Recursion Pharmaceuticals' net margin of -4,136.55%. Recursion Pharmaceuticals' return on equity of -46.59% beat Fusion Pharmaceuticals' return on equity.
Fusion Pharmaceuticals has higher earnings, but lower revenue than Recursion Pharmaceuticals. Fusion Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Fusion Pharmaceuticals received 20 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 64.06% of users gave Fusion Pharmaceuticals an outperform vote while only 51.22% of users gave Recursion Pharmaceuticals an outperform vote.
Fusion Pharmaceuticals presently has a consensus target price of $20.25, suggesting a potential downside of 5.73%. Recursion Pharmaceuticals has a consensus target price of $12.75, suggesting a potential upside of 48.26%. Given Fusion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Fusion Pharmaceuticals.
Fusion Pharmaceuticals has a beta of -0.69, meaning that its share price is 169% less volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.
In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Fusion Pharmaceuticals. MarketBeat recorded 15 mentions for Recursion Pharmaceuticals and 12 mentions for Fusion Pharmaceuticals. Fusion Pharmaceuticals' average media sentiment score of 0.52 beat Recursion Pharmaceuticals' score of -0.06 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.
Summary
Recursion Pharmaceuticals beats Fusion Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Recursion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Recursion Pharmaceuticals Competitors List
Related Companies and Tools
